Ceftriaxone Pulse Dose for Post-Treatment Lyme Disease
Phase 1, Randomized, Double-Blind, Placebo-Controlled Trial of Pulse Dosed Ceftriaxone for Post-Treatment Lyme Disease
Sponsor: State University of New York - Upstate Medical University
Listed as NCT06611111, this EARLY_PHASE1 trial focuses on Post-Treatment Lyme Disease and remains actively recruiting participants. Sponsored by State University of New York - Upstate Medical University, it has been updated 5 times since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
5 versions recorded-
Feb 2026 — Present [monthly]
Recruiting EARLY_PHASE1
-
Mar 2025 — Feb 2026 [monthly]
Recruiting EARLY_PHASE1
-
Jan 2025 — Mar 2025 [monthly]
Recruiting EARLY_PHASE1
Status: Not Yet Recruiting → Recruiting
-
Nov 2024 — Jan 2025 [monthly]
Not Yet Recruiting EARLY_PHASE1
Status: Recruiting → Not Yet Recruiting
-
Oct 2024 — Nov 2024 [monthly]
Recruiting EARLY_PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- State University of New York - Upstate Medical University
- Steven & Alexandra Cohen Foundation
For direct contact, visit the study record on ClinicalTrials.gov .